United States — Food and Drug Administration & ImmunityBio
3 shared events · Importance 4 · Last updated May 09, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
NewsDesk Dashboard
Regulatory
United States — Food and Drug Administration: The United States — Food and Drug Administration sent a warning letter to ImmunityBio regarding misleading efficacy claims made about Anktiva, which triggered the class action lawsuits.
ImmunityBio: ImmunityBio is facing a securities class action lawsuit for allegedly making misleading claims about its product Anktiva, which caused its stock price to drop and market capitalization to decrease by nearly $2 billion.
Apr 02, 2026 · 42 articles
Regulatory
United States — Food and Drug Administration: The United States — Food and Drug Administration issued a warning letter to ImmunityBio, Inc. regarding misleading promotional communications for Anktiva, which led to the company's stock decline and subsequent lawsuit.
ImmunityBio: ImmunityBio is facing a securities class action lawsuit due to a significant drop in its stock price following a US Food and Drug Administration warning letter regarding misleading advertisements for its cancer therapy, Anktiva.
May 01, 2026 · 7 articles
95
United States — Food and Drug Administration sent warning letter ImmunityBioImmunityBio Faces Anktiva...
90
United States — Food and Drug Administration issued warning letter ImmunityBioImmunityBio FDA Warning, Stock Drop
NEWSDESK
Explore this relationship live
Track how United States — Food and Drug Administration and ImmunityBio interact across events, view sentiment trends, and discover connected entities.
Open Dashboard